1998
DOI: 10.1016/s0168-8278(98)80974-4
|View full text |Cite
|
Sign up to set email alerts
|

Amantadine for chronic hepatitis C

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
1
1

Year Published

1999
1999
2001
2001

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 2 publications
0
1
1
Order By: Relevance
“…5,21 On the other hand, in other studies, rates of 9.1% to 31% therapy termination were reported because of side effects. 6,7,10 In conclusion, this study does not support the findings of the Smith pilot study. 4 Amantadine therapy in CH-C patients may be effective for reducing biochemical markers, but not for the eradication of HCV RNA.…”
Section: Discussioncontrasting
confidence: 87%
See 1 more Smart Citation
“…5,21 On the other hand, in other studies, rates of 9.1% to 31% therapy termination were reported because of side effects. 6,7,10 In conclusion, this study does not support the findings of the Smith pilot study. 4 Amantadine therapy in CH-C patients may be effective for reducing biochemical markers, but not for the eradication of HCV RNA.…”
Section: Discussioncontrasting
confidence: 87%
“…Unfortunately, this biochemical response was not sustained, and ALT returned to pretreatment levels when therapy was discontinued. In contrast to the encouraging results reported by Smith, other studies have demonstrated no significant decrease in HCV RNA with amantadine 200 mg daily monotherapy [5][6][7][8][9][10][11][12][13] (Table 4). However, the number of patients enrolled in those studies was relatively small, too small to confirm the efficacy of amantadine monotherapy in patients with CH-C.…”
Section: Discussionmentioning
confidence: 89%